8-K: AbbVie Reports Mixed Full-Year and Q4 2023 Results, Announces Strategic Acquisitions

AbbVie's full-year 2023 results show a decrease in GAAP EPS and revenue, impacted by Humira biosimilar competition, but the company is making strategic acquisitions and raising long-term outlook for key products.

Summary

• AbbVie reported full-year 2023 net revenues of $54.318 billion, a decrease of 6.4% on a reported basis.
• Full-year diluted EPS was $2.72 on a GAAP basis, a decrease of 59.0%, and adjusted diluted EPS was $11.11, a decrease of 19.3%.
• The company's immunology portfolio saw a 9.6% decrease in revenue due to Humira biosimilar competition, with Humira revenues declining to $14.404 billion.
• Skyrizi and Rinvoq revenues showed strong growth, with Skyrizi reaching $7.763 billion and Rinvoq at $3.969 billion.
• The neuroscience portfolio experienced an 18.2% increase in revenue, driven by Botox Therapeutic and Vraylar.
• AbbVie announced definitive agreements to acquire ImmunoGen for approximately $10.1 billion and Cerevel Therapeutics for approximately $8.7 billion.
• The company provided 2024 adjusted diluted EPS guidance of $11.05 to $11.25, including a $0.32 per share dilutive impact from the acquisitions.
• AbbVie reaffirmed its expectation for high single-digit compound annual revenue growth through 2029 and raised its 2027 combined sales outlook for Skyrizi and Rinvoq to more than $27 billion.
• Peak sales outlook for Ubrelvy and Qulipta were raised to more than $3 billion combined.

Sentiment

Score: 6

Explanation: The sentiment is mixed. While there are positive aspects like the acquisitions and growth in some product lines, the significant decline in EPS and Humira revenue temper the overall outlook. The company is taking steps to address future growth, but the current results are not overwhelmingly positive.

Positives

• Skyrizi and Rinvoq demonstrated strong revenue growth, offsetting some of the Humira decline.
• The neuroscience portfolio showed significant growth, driven by key products like Botox Therapeutic and Vraylar.
• The acquisitions of ImmunoGen and Cerevel Therapeutics are expected to strengthen AbbVie's oncology and neuroscience pipelines.
• AbbVie reaffirmed its long-term growth outlook and raised sales expectations for key products.
• The company is actively investing in R&D and bolstering its pipeline.

Negatives

• Full-year GAAP diluted EPS decreased significantly by 59.0% due to various factors including acquired IPR&D and milestones expense.
• Humira revenues experienced a substantial decline due to biosimilar competition.
• The oncology portfolio saw a decrease in revenue of 10.1% on a reported basis.
• The company's overall net revenues decreased by 6.4% on a reported basis.
• The acquisitions will have a dilutive impact on 2024 EPS.

Risks

• The ongoing impact of Humira biosimilar competition poses a significant risk to revenue.
• The integration of ImmunoGen and Cerevel Therapeutics may present challenges.
• The company faces risks related to intellectual property, competition, and regulatory changes.
• There is a risk that the acquisitions may not be consummated on the anticipated timeframe or at all.
• The costs to consummate the acquisitions could be greater than expected.

Future Outlook

AbbVie expects modest operational revenue growth in 2024, followed by a return to robust growth in 2025 and a high single-digit CAGR through 2029. The company also raised its long-term outlook for Skyrizi, Rinvoq, Ubrelvy and Qulipta.

Management Comments

• 2023 was another outstanding year, marked by strong operational execution and significant overperformance from our non-Humira growth platform.
• During the year we meaningfully increased R&D investment and bolstered our pipeline with the proposed ImmunoGen and Cerevel Therapeutics acquisitions.
• 2024 is an exciting year for AbbVie, as we are well positioned to fully absorb Humira erosion and achieve modest operational revenue growth, followed by a return to robust growth in 2025 and a high single-digit CAGR through the end of the decade.

Industry Context

The results reflect the ongoing impact of biosimilar competition on established pharmaceutical products like Humira. The acquisitions of ImmunoGen and Cerevel Therapeutics demonstrate a strategic move to diversify and strengthen AbbVie's pipeline in key therapeutic areas, aligning with industry trends of companies seeking growth through acquisitions and innovation.

Comparison to Industry Standards

• The decline in Humira revenue is consistent with the expected impact of biosimilar competition, a trend seen across the pharmaceutical industry for blockbuster drugs losing patent protection.
• The growth of Skyrizi and Rinvoq is a positive sign, indicating AbbVie's ability to develop and commercialize new products to offset revenue losses from older drugs, similar to strategies employed by companies like Novartis and Pfizer.
• The acquisitions of ImmunoGen and Cerevel Therapeutics are comparable to other large pharmaceutical companies acquiring biotech firms to enhance their pipelines, such as Merck's acquisition of Acceleron Pharma.
• AbbVie's long-term growth outlook and increased sales expectations for key products are similar to the strategies of other major pharmaceutical companies aiming for sustained growth through innovation and strategic acquisitions.

Stakeholder Impact

• Shareholders may be concerned about the decrease in EPS and revenue, but encouraged by the strategic acquisitions and long-term growth outlook.
• Employees may experience changes due to the acquisitions and integration processes.
• Customers will benefit from the development of new and innovative therapies.
• Suppliers may see changes in demand based on the company's product portfolio.
• Creditors will monitor the company's financial performance and debt levels.

Next Steps

• AbbVie will focus on integrating ImmunoGen and Cerevel Therapeutics.
• The company will continue to advance its clinical programs, including lutikizumab in HS.
• AbbVie will present data from the LUMINOSITY trial at a future medical meeting.
• The company will discuss with global health authorities the potential to support an accelerated approval for telisotuzumab-vedotin.
• AbbVie will continue to develop and commercialize new products to offset revenue losses from older drugs.

Key Dates

Keywords

AbbVie, Humira, Skyrizi, Rinvoq, Immunology, Oncology, Neuroscience, Aesthetics, Acquisition, ImmunoGen, Cerevel Therapeutics, EPS, Revenue, Biosimilar, Pharmaceuticals